Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies.
Reimann P, Petzer V, Mündlein A, Hartmann B, Severgnini L, Winkler A, Lang T, Huynh M, Gasser K, Rüger J, Atzl M, Mink S, Fraunberger P, Schmidt S, Steiner N, Griesmacher A, Gunsilius E, Nachbaur D, Willenbacher W, Wolf D, Winder T, Benda MA. Reimann P, et al. Among authors: severgnini l. Ann Hematol. 2024 Jun;103(6):2123-2131. doi: 10.1007/s00277-024-05671-6. Epub 2024 Mar 2. Ann Hematol. 2024. PMID: 38436671
Cell-free circulating RAS mutation concentrations significantly impact the survival of metastatic colorectal cancer patients.
Muendlein A, Geiger K, Heinzle C, Gaenger S, Winder T, Severgnini L, Reimann P, Brandtner EM, Leiherer A, Drexel H, Decker T, Nonnenbroich C, Dechow T. Muendlein A, et al. Among authors: severgnini l. J Cancer Res Clin Oncol. 2023 Aug;149(9):6435-6444. doi: 10.1007/s00432-023-04623-3. Epub 2023 Feb 10. J Cancer Res Clin Oncol. 2023. PMID: 36763171
Correlation between the level of evidence and the class of recommendations concerning the pharmacological aspects of the Guidelines of the European Society of Cardiology.
Milbradt S, Eichhorn J, Fetzner U, Fietz R, Gross R, Jung K, Klement M, Konzett K, Larcher B, Manz B, Mareth C, Schmieder E, Severgnini L, Sternbauer S, Wehrli MRT, Weifenbach N, Saely C, Drexel H. Milbradt S, et al. Among authors: severgnini l. Int J Cardiol. 2023 Mar 15;375:119-123. doi: 10.1016/j.ijcard.2022.12.027. Epub 2022 Dec 16. Int J Cardiol. 2023. PMID: 36535563
SARS-CoV-2 RBD-specific and NP-specific antibody response of healthcare workers in the westernmost Austrian state Vorarlberg: a prospective cohort study.
Atzl M, Muendlein A, Winder T, Fraunberger P, Brandtner EM, Geiger K, Klausberger M, Duerkop M, Sprenger L, Mutschlechner B, Volgger A, Benda M, Severgnini L, Jaeger JB, Drexel H, Lang A, Leiherer A. Atzl M, et al. Among authors: severgnini l. BMJ Open. 2022 May 24;12(5):e052130. doi: 10.1136/bmjopen-2021-052130. BMJ Open. 2022. PMID: 35613821 Free PMC article.
SARS-CoV-2-related mortality and treatment delays for cancer patients in Austria : Findings of a multicentric nationwide study.
Berger JM, Wohlfarth P, Königsbrügge O, Knaus HA, Porpaczy E, Kaufmann H, Schreiber J, Mrva-Ghukasyan T, Winder T, Severgnini L, Wolf D, Petzer V, Nguyen VA, Weinlich G, Öhler L, Wonnerth A, Miksovsky A, Engelhart B, Preusser M, Berghoff AS. Berger JM, et al. Among authors: severgnini l. Wien Klin Wochenschr. 2022 May;134(9-10):371-376. doi: 10.1007/s00508-022-02006-1. Epub 2022 Feb 16. Wien Klin Wochenschr. 2022. PMID: 35171337 Free PMC article.
Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haemato-oncological patients with no antibody response.
Reimann P, Ulmer H, Mutschlechner B, Benda M, Severgnini L, Volgger A, Lang T, Atzl M, Huynh M, Gasser K, Grabher C, Mink S, Fraunberger P, Petrausch U, Hartmann B, Winder T. Reimann P, et al. Among authors: severgnini l. Br J Haematol. 2022 Feb;196(3):577-584. doi: 10.1111/bjh.17982. Epub 2021 Dec 6. Br J Haematol. 2022. PMID: 34872162 Clinical Trial.
Serological SARS-CoV-2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID-19 vaccine in haematological and oncological patients.
Benda M, Mutschlechner B, Ulmer H, Grabher C, Severgnini L, Volgger A, Reimann P, Lang T, Atzl M, Huynh M, Gasser K, Petrausch U, Fraunberger P, Hartmann B, Winder T. Benda M, et al. Among authors: severgnini l. Br J Haematol. 2021 Nov;195(4):523-531. doi: 10.1111/bjh.17743. Epub 2021 Aug 3. Br J Haematol. 2021. PMID: 34346068 Free PMC article.